Leadership Transition at Vetter: Thomas Otto Retires

Portrait des Geschäftsführers Thomas Otto

After more than 35 years, including 23 years on the management board, Thomas Otto is entering his well-deserved retirement. He will continue to support us in an advisory role. The transition to an experienced leadership team was planned early and strategically to ensure continuity and stability.

Through his clear leadership and commitment, Thomas Otto has been instrumental in shaping the sustainable development and continued growth of the company. Our success as a trusted partner to global biopharmaceutical companies for the production of life-enhancing medicines is partially due to his strong and reliable leadership alongside his management colleagues. 

"Thomas Otto has decisively advanced our family business with his vision, innovative strength and great sense of responsibility. His contribution to Vetter's development and internationalization is outstanding and deserves the highest recognition," says Senator h.c. Udo J. Vetter, Chairman of the Advisory Board and member of the owner family. "For more than three decades, he was a reliable designer, initiator and bridge builder – both within the company and externally. On behalf of the Vetter family and the advisory board, I would like to thank him for his extraordinary commitment and lasting impact on our success story."

In his advisory role, he will contribute his extensive knowledge and decades of experience with pharmaceutical construction projects to the planned development of a new production site in Germany. 

Portraitbild der Geschäftsführung Thomas Otto

"I am grateful for the many years at Vetter and proud of what we have achieved together. I am extremely pleased that I was able to contribute to making the company strong and fit to take on the future. I wish my colleagues in the management team continued success in leading Vetter with competence and passion," shared Thomas Otto.

Thomas Otto, long-standing Managing Director Production/Engineering/Technical Services

Strategic Succession Planning Ensures Continuity

The strategic planning for the new structure of the our management team already started earlier. We have appointed long-standing executives Henryk Badack, Titus Ottinger, and Carsten Press to the Management Board as Managing Directors at the beginning of 2025. With their in-depth understanding of the company, its customers and the industry, they are making a significant contribution our sustainable future and the trust towards the owner family and the company Advisory Board. 

We remain a trusted partner for our customers, employees, partners and the region. As a globally active CDMO we continue to stand for quality and stability, strong partnerships and sustainable development. In close collaboration with our customers, we significantly contribute to life-enhancing medicines that are readily available to help patients around the world achieve a better quality of life.